Compare AbCellera Biologics Inc (ABCL) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Enbridge Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Enbridge Inc trades at $55.15 (market cap $120.14B). The key difference: Enbridge Inc is far larger — about 51.1× AbCellera Biologics Inc's market cap, and Enbridge Inc pays a 5.11% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ENB | |
|---|---|---|
Market Cap | $2.35B | $120.14B |
Sector | Health | Energy |
52-Week High | $8.12 | $58.04 |
52-Week Low | $2.78 | $43.79 |
Enterprise Value | $1.99B | $200.94B |
Dividend Yield | — | 5.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Enbridge (ENB) trades at $55.05, up 1.79% for the day, with a bearish technical signal from moving averages. The company reported strong revenue growth to $65.19B in 2025 and a net income margin of 10%, though it missed Q3 2025 EPS estimates. Recent news highlights include a dividend payment of $0.97 and upcoming Q2 2026 earnings on July 31, 2026. Analyst consensus is split evenly between Buy and Hold ratings.
Outlook remains mixed with solid cash flow from operations supporting dividends, but debt levels have risen to 48.81% of assets. Key risks include energy market volatility and execution of growth projects. The stock offers a high yield but faces near-term technical pressure and valuation concerns at a P/E of 25.73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
